Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than corporate financial performance.
Material Changes
The material change reported is an increase in the personal holdings of specific directors and executives following the re-investment of dividends paid on April 7, 2011. No comparative financial data or prior period analysis is included in this filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of specific share purchase transactions.
Important Facts for Investors
- Transaction Type: Directors and executives increased their holdings via dividend re-investment.
- Share Prices: Ordinary shares were purchased at £12.38 per share on April 12, 2011; ADRs were purchased at $39.96 per ADR on April 7, 2011.
- Key Participants: Notable increases were recorded for Dr. M M Slaoui (196.67 shares), Mr. J M Clarke (501.50 shares), and Mr. J R Stéphenne (742.05 shares).
- Regulatory Basis: The notification complies with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).